PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry
dc.contributor.author | Casas, J. P. | en |
dc.contributor.author | Ninio, E. | en |
dc.contributor.author | Panayiotou, A. | en |
dc.contributor.author | Palmen, J. | en |
dc.contributor.author | Cooper, J. A. | en |
dc.contributor.author | Ricketts, S. L. | en |
dc.contributor.author | Sofat, R. | en |
dc.contributor.author | Nicolaides, A. N. | en |
dc.contributor.author | Corsetti, J. P. | en |
dc.contributor.author | Fowkes, F. G. | en |
dc.contributor.author | Tzoulaki, I. | en |
dc.contributor.author | Kumari, M. | en |
dc.contributor.author | Brunner, E. J. | en |
dc.contributor.author | Kivimaki, M. | en |
dc.contributor.author | Marmot, M. G. | en |
dc.contributor.author | Hoffmann, M. M. | en |
dc.contributor.author | Winkler, K. | en |
dc.contributor.author | Marz, W. | en |
dc.contributor.author | Ye, S. | en |
dc.contributor.author | Stirnadel, H. A. | en |
dc.contributor.author | Boekholdt, S. M. | en |
dc.contributor.author | Khaw, K. T. | en |
dc.contributor.author | Humphries, S. E. | en |
dc.contributor.author | Sandhu, M. S. | en |
dc.contributor.author | Hingorani, A. D. | en |
dc.contributor.author | Talmud, P. J. | en |
dc.date.accessioned | 2015-11-24T18:58:20Z | |
dc.date.available | 2015-11-24T18:58:20Z | |
dc.identifier.issn | 1524-4539 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19268 | |
dc.rights | Default Licence | - |
dc.subject | 1-Alkyl-2-acetylglycerophosphocholine Esterase/*metabolism | en |
dc.subject | Case-Control Studies | en |
dc.subject | Coronary Disease/enzymology/*epidemiology/genetics | en |
dc.subject | Cross-Sectional Studies | en |
dc.subject | Europe | en |
dc.subject | Genotype | en |
dc.subject | Humans | en |
dc.subject | Phospholipases A2/*genetics | en |
dc.subject | Polymorphism, Single Nucleotide/genetics | en |
dc.subject | Prospective Studies | en |
dc.subject | Risk Factors | en |
dc.title | PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry | en |
heal.abstract | BACKGROUND: Higher lipoprotein-associated phospholipase A(2)(Lp-PLA2) activity is associated with increased risk of coronary heart disease (CHD), making Lp-PLA2 a potential therapeutic target. PLA2G7 variants associated with Lp-PLA2 activity could evaluate whether this relationship is causal. METHODS AND RESULTS: A meta-analysis including a total of 12 studies (5 prospective, 4 case-control, 1 case-only, and 2 cross-sectional studies; n=26 118) was undertaken to examine the association of the following: (1) Lp-PLA2 activity versus cardiovascular biomarkers and risk factors and CHD events (2 prospective studies; n=4884); (2) PLA2G7 single-nucleotide polymorphisms and Lp-PLA2 activity (3 prospective, 2 case-control, 2 cross-sectional studies; up to n=6094); and (3) PLA2G7 single-nucleotide polymorphisms and angiographic coronary artery disease (2 case-control, 1 case-only study; n=4971 cases) and CHD events (5 prospective, 2 case-control studies; n=5523). Lp-PLA2 activity correlated with several CHD risk markers. Hazard ratios for CHD events for the top versus bottom quartile of Lp-PLA2 activity were 1.61 (95% confidence interval, 1.31 to 1.99) and 1.17 (95% confidence interval, 0.91 to 1.51) after adjustment for baseline traits. Of 7 single-nucleotide polymorphisms, rs1051931 (A379V) showed the strongest association with Lp-PLA2 activity, with VV subjects having 7.2% higher activity than AAs. Genotype was not associated with risk markers, angiographic coronary disease (odds ratio, 1.03; 95% confidence interval, 0.80 to 1.32), or CHD events (odds ratio, 0.98; 95% confidence interval, 0.82 to 1.17). CONCLUSIONS: Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest effects on Lp-PLA2 activity were not associated with cardiovascular risk markers, coronary atheroma, or CHD. Larger association studies, identification of single-nucleotide polymorphisms with larger effects, or randomized trials of specific Lp-PLA2 inhibitors are needed to confirm or refute a contributory role for Lp-PLA2 in CHD. | en |
heal.access | campus | - |
heal.fullTextAvailability | TRUE | - |
heal.identifier.primary | 10.1161/CIRCULATIONAHA.109.923383 | - |
heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20479152 | - |
heal.identifier.secondary | http://circ.ahajournals.org/content/121/21/2284.full.pdf | - |
heal.journalName | Circulation | en |
heal.journalType | peer-reviewed | - |
heal.language | en | - |
heal.publicationDate | 2010 | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
heal.type | journalArticle | - |
heal.type.el | Άρθρο Περιοδικού | el |
heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: